Jeito Capital co-leads a EUR 104 million financing in Noema Pharma, a clinical-stage biopharma company targeting debilitating central nervous system disorders

Jeito Capital co-leads a EUR 104 million financing in Noema Pharma,
a clinical-stage biopharma company targeting
debilitating central nervous system disorders

  • Noema Pharma’s clinical-stage assets and diversified pipeline hold significant potential in developing effective therapeutic options for patients with debilitating central nervous system (CNS) disorders, addressing high unmet medical needs
  • Jeito Capital’s investment in Noema Pharma marks its second in the field of neurological disorders and represents a significant opportunity to support this promising therapeutic area with high growth potential
  • Through its investment, Jeito Capital aims to promote the expansion and acceleration of Noema’s development activities and bolster value creation in France and in Europe, reinforcing its dedication to fostering the growth of biopharmaceutical champions in the region

Paris, France, March 7th 2023 – Jeito Capital (“Jeito”), the largest fully independent private equity firm dedicated to healthcare and biopharma in Europe, announced today that it has co-led a EUR 104 million (CHF 103 million, approx. USD 112 million) financing in Noema Pharma (the “Company”), a clinical-stage biopharma company targeting debilitating central nervous system (CNS) disorders. Noema Pharma has offices in Switzerland, France, and in the US.

The oversubscribed financing was co-led by Jeito and Forbion with participation from new investors such as the UPMC Enterprises joined by existing investors Sofinnova Partners, Polaris Partners, Gilde Healthcare and Invus.

Founded in 2019 in Paris, France, Noema Pharma currently has multiple active Phase 2b clinical trials in highly undertreated CNS conditions including seizures in Tuberous Sclerosis Complex, severe pain in Trigeminal Neuralgia and Childhood Onset Fluency Disorder. The Company has also completed a Phase 2a clinical trial in adult patients with Tourette Syndrome that is currently being extended to adolescents. As part of its indication expansion strategy, the Company also anticipates initiating clinical development in Atypical Depression and Binge Eating Disorders.

Proceeds from the financing will primarily be used to advance the Company’s clinical-stage assets.

Jeito selected Noema Pharma in line with its investment strategy of supporting the development of the most promising European biopharma companies with high growth and acceleration potential. As Jeito’s second investment in a biopharma company targeting neurological diseases, Noema Pharma’s maturing clinical-stage pipeline shows great promise for helping patients who currently lack effective treatments or face unmet medical needs.

In addition, Jeito will invest in Noema Pharma SAS (France), enabling it to expand its clinical trials and safety monitoring efforts in France and in Europe. This is expected to create new job opportunities and provide support for French and European suppliers in the manufacturing process. Rachel Mears, Partner at Jeito Capital, will join Noema Pharma’s Board of Directors.

Dr Rafaèle Tordjman, MD, PhD, Founder and CEO of Jeito Capital, commented “We are excited to partner with Noema Pharma in their mission to accelerate the development of innovative treatments for debilitating CNS disorders. I am particularly proud that the company born in Paris three years ago, which developed in Switzerland and the US, continues to create value in France and Europe. This reflects Jeito Capital’s strong commitment to fostering the emergence of potential global biopharma leaders from Europe. As Jeito Capital’s second investment in a neurology company, Noema Pharma with its clinical-stage assets and diversified pipeline has shown significant potential for the development of effective innovative therapies for the benefit of patients.”

Rachel Mears, Partner at Jeito Capital added: One of the pillars of our investment strategy is to deploy capital in truly differentiated and innovative therapies with high unmet medical need. The clinical work being undertaken by Noema Pharma fit these criteria exactly. The expertise, quality and dedication of the Noema team are clear to see in their development work and position the Company as an upcoming global CNS leader. We are excited to partner with Noema Pharma to accelerate its mission of developing effective solutions for patients with CNS disorders and are committed to supporting their continued growth and success.”

Luigi Costa, Chief Executive Officer of Noema Pharma said: We are excited to announce the successful completion of this oversubscribed Series B financing round and very pleased to have a world-class group of investors supporting our vision of bringing much-needed treatments to those living with debilitating central nervous system disorders. We welcome our new investors who bring extensive expertise and knowledge of drug development and company building and add further strength to our robust investor base. This financing comes at a key time for Noema Pharma as we look forward to extensive news flow over the next 24 months.

About Jeito Capital

Jeito Capital is a global leading Private Equity company with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports managers through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients’ access globally, especially in Europe and the United States. Jeito Capital has €534 million under management and a rapidly growing portfolio of investments. Jeito Capital is based in Paris with a presence in Europe and the United States.

@Jeito_lifeLinkedInFor more information, please visit www.jeito.life, or follow @Jeito_life on Twitter or LinkedIn.
About Noema Pharma

Noema Pharma (www.noemapharma.com) is a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders characterized by imbalanced neuronal networks. The Company has a well differentiated pipeline with four mid clinical-stage therapeutic product candidates in-licensed from Roche. Noema currently has 3 active Phase 2b clinical trials in highly undertreated CNS conditions: seizures in Tuberous Sclerosis Complex, severe pain in Trigeminal Neuralgia and Childhood Onset Fluency Disorder. The Company has completed a Phase 2a clinical trial in adult patients with Tourette Syndrome that is currently being extended with an adolescent cohort. The Company has also completed preclinical validation studies in Atypical Depression and Binge Eating Disorder. Noema Pharma was founded in 2019 by the leading venture capital firm Sofinnova Partners. Additional investors include Biomed Partners, Forbion, Gilde Healthcare, Invus, Jeito Capital, Polaris Partners, UPMC Enterprises, and an undisclosed investor.

For further information please contact:

Jeito Capital
Rafaèle Tordjman, Founder & CEO
Assia Mouhout, EA
Tel : +33 6 76 49 37 94

Consilium Strategic Communications Mary-Jane Elliott / Davide Salvi / Kris Lam
Jeito@consilium-comms.com
Tel: +44 (0) 20 3709 5700

Marion Bougeard
marion@achto-conseil.fr
Tel : +33 6 76 73 57 31

GlobeNewswire Distribution ID 1000796612

United in our Efforts to Accelerate Towards Gender Equality!

The theme for the International Women’s Day this year (IWD 2023) is the impact of virtual and technological progress in all spheres of life: “DigitALL: Innovation and technology for gender equality”.

We are delighted to be united in our collective efforts to accelerate the achievement of gender equality!

Coming out of a few years of COVID-19 impact, when too many of us spent too much time in the virtual world, it is essential to consider how digitalisation and innovation can be a source for gender equality and equity, for promoting rights and choices! The washing machine, the microwave oven, the contraceptive pill were all revolutionary in their time. They improved the lives of generations of women before us, leaving them more time for themselves and givingthem control over their own bodies. What new technological breakthroughs will be game changers for a more gender equal world for the next generation of women and girls?

We can share some of the results and impacts we would like to see from an increasingly digitalised world with innovative technology. So here are some of our thoughts to innovators and disruptors of conventions. We would like to see access to online information and opportunities equalised; we would like to see safety for women, girls and vulnerable groups in online spaces; we would like to see accountability of those in power to make these spaces equal and safe for women and girls, irrespective of their sexual orientation. Sexual orientation and gender identity are integral aspects of ourselves and should never lead to discrimination or abuse.

The Lao PDR consistently supports progressive international conversations and consensus around women’s rights, many of which are reflected in national laws and policies. Innovations such as the ‘Noi Framework’ in Laos highlight the demographic case for investments in the adolescent girl, receiving widespread Government support. During and after the COVID-19 pandemic, telehealth for maternal health was initiated and will now be mainstreamed, and remote counselling for mental health and psychosocial well-being of individuals was increased. Education curricula were improved, including Comprehensive Sexuality Education access through online videos, and the Noi Yakhoo Application was launched. These are all relevant and important initiatives, aimed also at reducing the digital divide in Laos, as a pre-condition to make technology accessible to all.

Aligned with this year’s IWD theme, here are four areas we think require urgent attention in Laos:

Literacy and education: COVID-19 increased school dropout rates. Today, proactive enrolment and retention in schools of girls and boys need to be ensured. Providing teachers and students with better digital skills and access to technologies can help keep girls in school, especially amongst the poorest, while diverse learning opportunities in person and online, such as Khang Panya, should be accessible to those who have dropped out.

Health and Mental health: To protect maternal health, increase, in particular national budgets for contraceptives and maternal health. Women who can choose if, when and how many children to have, will access more opportunities for themselves and their children. Family planning gives the highest return on investment within the Reproductive, Maternal, Newborn, Child and Adolescent Health (RMNCAH) and Nutrition, and can also reduce stunting in children under 5 by over 5.4%. Expanding services such as telehealth can ensure uninterrupted access to reproductive health information, services and care for women and girls. While remote counselling and de-stigmatising access to mental health for all, women and girls as well as men and boys can improve women’s safety and security.

Finance and economic empowerment: Less than one-third of women have bank accounts with a financial institution. Only 2.2% of women-led businesses use information communication technology to sell their products compared to 3.3% of men-led businesses. In a survey on access to trade finance, 70% of businesswomen reported that their credit applications were totally or partially rejected. E-business and e-banking have great potential for expanding women’s access to finance and business, but technology must be combined with effective financial, digital, and entrepreneurship literacy and accessibility.

Safety in person and online: Data shows that just like in real life, women and girls are targeted far more online. This is known as technology facilitated gender-based violence (TFGBV). This has severe impacts on their mental well-being as well as safety and security. Raise awareness of protection laws that exist and increase online protection mechanisms, for example, by promoting public campaigns such as #bodyright, which rolled out in 2022 in Laos.

So please, as you celebrate yourself or the women and girls in your lives, take a moment to consider their rights and their choices. It’s a day to consider whether technology and innovation around you are inclusive of the rights of women and girls, [of vulnerable groups, of LGBTIQ+], if it keeps them safe and ideally expands their opportunities!

Happy International Women’s Day from us to you! We are convinced that if we work together, build on each other’s efforts, next year we can celebrate accelerated progress in Laos for use of technology and innovation to protect the rights and choices of women and girls!

Source: Lao News Agency

Small but Steady: Journey to Realise Noi’s Dream

By the road towards the country’s largest gold mine in Sepon, Savannakhet Province, lie peaceful villages where five girls began their journey to realize their dreams, coordinated by the Ministry of Education and Sports (MoEs) and UNFPA, in partnership with Crowne Plaza Vientiane, Pakpasak Technical College and partners.

Today, the second batch of Five Nang Noi mentors officially completed a three-month training programme to acquire culinary skills, strengthen their financial literacy and life skills with Crowne Plaza Vientiane Hotel, Pakpasak Technical College, Banque Franco-Lao (BFL) Bank and the Vientiane Youth Centre.

Mr Sisana Boupha, Director-General of Non-Formal Education, Ministry of Education and Sports said, “As a part of the Nang Noi Girls Group Programme, this initiative helps minimise the knowledge gap in Comprehensive Sexuality Education and equality between urban and rural. The programme also efficiently improves the non-formal education in Laos and contributes to the 9th five-year Education and Sports Development Plan (2021-2025) so that everyone can improve their life skills and live their life with joy and stability.”

Keota, Thongmai, Khen, Honey, and Lampheng, five of the Nang Noi mentors, arrived in Vientiane in November 2022 to hone their skills and ignite their potential for entrepreneurship, which will contribute to Laos’ economic growth. This innovative endeavor comes from the “Noi ecosystem” which also promotes partnerships between the public and private sector to support Nang Noi Girls in their path towards empowerment.

Mariam A. Khan said, “These promising young girls represent the hopes and dreams of over 720,000 Lao adolescent girls. With this unique learning opportunity, the sky is the limit for them! UNFPA stands by every single one of them to realise their dreams. ”

Mr Nattawut Wetprasit, Director of Operations and HR, said, “Crowne Plaza Vientiane is very proud of all the five girls, and we are glad to be a part of the second batch of this meaningful programme. Crowne Plaza will continue our support on their income generation and help set up their businesses back in their hometown.”

Mr Saysamone Ngamsy, Director of Pakpasak Technical College, said, “Our college is pleased to contribute to the Nang Noi mentors programme as we are fully equipped with facilities and human resources to provide the necessary training. We are delighted to work with all partners and hope to continue this effort in empowering our young women from the rural area.”

Ms Honey Vixaykoumman, one of the mentors from Alai Yai village, shared her reflection on the three-month programme “I am just an ordinary girl from an outskirt part of the town where my house sits right next to the forest. Back in Sepon, I learned so much from my four years under the Nang Noi mentor programme. And now, with this opportunity in the big city, I am even more confident, I have many new skills, know how to plan my future and am more knowledgeable on my sexual and reproductive health.”

Source: Lao News Agency